MCID: INT079
MIFTS: 50

Intrahepatic Cholangiocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases

Aliases & Classifications for Intrahepatic Cholangiocarcinoma

MalaCards integrated aliases for Intrahepatic Cholangiocarcinoma:

Name: Intrahepatic Cholangiocarcinoma 12 52 6 15 17 71
Cholangiocarcinoma 43 71
Peripheral Intrahepatic Cholangiocarcinoma 71
Intrahepatic Bile Duct Carcinoma 12
Peripheral Cholangiocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4928
MeSH 43 D018281
NCIt 49 C35417
ICD10 32 C22.1
UMLS 71 C0206698 C0345905 C3273048

Summaries for Intrahepatic Cholangiocarcinoma

NIH Rare Diseases : 52 Intrahepatic cholangiocarcinoma is a cancer that develops in the cells within the bile ducts; both inside and outside the liver. The terms cholangiocarinoma and bile duct cancer are often used to refer to the same condition. This condition occurs slightly more often in males than females and usually affects people who are between 50-70 years old. Signs and symptoms of intrahepatic cholangiocarcinoma include jaundice , abdominal pain, fever, weight loss, weakness and itching. Treatment options may include surgery to remove the bile duct and parts of the liver, chemotherapy and radiation.

MalaCards based summary : Intrahepatic Cholangiocarcinoma, also known as cholangiocarcinoma, is related to mucinous intrahepatic cholangiocarcinoma and sarcomatous intrahepatic cholangiocarcinoma, and has symptoms including abdominal pain and malaise. An important gene associated with Intrahepatic Cholangiocarcinoma is CCAT1 (Colon Cancer Associated Transcript 1), and among its related pathways/superpathways are Central carbon metabolism in cancer and Cytosine methylation. The drugs Celecoxib and Desflurane have been mentioned in the context of this disorder. Affiliated tissues include liver, lymph node and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Intrahepatic Cholangiocarcinoma

Diseases related to Intrahepatic Cholangiocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 755)
# Related Disease Score Top Affiliating Genes
1 mucinous intrahepatic cholangiocarcinoma 35.0 MUC1 KRT7 IDH1
2 sarcomatous intrahepatic cholangiocarcinoma 34.8 MUC1 KRT7 KRT19 AFP
3 klatskin's tumor 33.6 KRT7 APC AFP
4 cholangiocarcinoma 33.1 TUG1 TP53 RASGEF1A MUC4 MUC1 KRT7
5 adenocarcinoma 31.7 TP53 MUC4 MUC1 KRT7 KRAS APC
6 bile duct adenoma 31.5 MUC1 KRT7 KRT19
7 tubular adenocarcinoma 31.5 MUC1 KRT7 AFP
8 lymphoepithelioma-like carcinoma 31.3 MUC1 KRT7 KRT19
9 adenoma 31.3 TP53 MUC1 KRT7 KRAS APC
10 biliary papillomatosis 31.3 MUC1 KRT7
11 hemangioma 31.2 TP53 MUC1 KRT7 KRAS IDH1
12 bile duct cancer 31.2 TP53 MUC4 MUC1 KRT7 KRT19 KRAS
13 pancreatic ductal adenocarcinoma 31.2 TP53 MUC4 MUC1 KRAS
14 cystadenocarcinoma 31.1 TP53 MUC1 KRT7
15 papillary adenocarcinoma 31.1 TP53 MUC1 KRT7 KRT19 KRAS
16 signet ring cell adenocarcinoma 31.0 TP53 MUC1 KRT7 KRAS
17 biliary tract disease 31.0 TP53 KRT7 KRT19 KRAS AFP
18 cavernous hemangioma 31.0 MUC1 KRT7 KRT19 AFP
19 colorectal adenocarcinoma 30.9 TP53 MUC1 KRT7 KRAS APC
20 pancreatic adenocarcinoma 30.9 TP53 MUC4 MUC1 KRT19 KRAS APC
21 intrahepatic bile duct adenoma 30.9 KRT7 KRT19 AFP
22 bile duct cystadenocarcinoma 30.9 MUC1 KRT7 AFP
23 bile duct disease 30.9 TP53 KRT7 KRT19 KRAS IDH1 AFP
24 cholecystitis 30.9 TP53 MUC4 MUC1
25 undifferentiated pleomorphic sarcoma 30.9 KRAS IDH2 IDH1
26 rectum adenocarcinoma 30.9 TP53 KRT7 KRAS
27 cystadenoma 30.9 MUC1 KRT7 AFP
28 appendix adenocarcinoma 30.8 KRT7 KRAS
29 adenofibroma 30.8 TP53 MUC1 KRT7 KRT19
30 angiosarcoma 30.8 TP53 MUC1 KRT7 KRAS
31 spindle cell carcinoma 30.8 MUC1 KRT7 KRT19
32 carcinosarcoma 30.8 TP53 MUC1 KRT7 KRAS
33 fibrolamellar carcinoma 30.7 KRT7 KRT19 AFP
34 breast ductal carcinoma 30.7 TP53 MUC1 KRT7 KRT19
35 neuroendocrine carcinoma 30.7 MUC1 KRT7 KRT19
36 benign mesothelioma 30.7 KRT7 AFP
37 krukenberg carcinoma 30.7 MUC1 KRT7
38 mucinous adenocarcinoma 30.7 TP53 MUC1 KRT7 KRT19 KRAS
39 squamous cell carcinoma 30.7 TUG1 TP53 MUC1 KRT19 CCAT2
40 ampulla of vater cancer 30.6 MUC1 KRT7 KRAS
41 adenosquamous carcinoma 30.6 TP53 MUC4 MUC1 KRT7 KRT19 KRAS
42 hepatoblastoma 30.5 TUG1 TP53 KRT7 APC AFP
43 biliary tract benign neoplasm 30.5 TP53 MUC1 KRT7 KRT19 KRAS
44 intrahepatic biliary papillomatosis 30.5 MUC1 KRAS AFP
45 villous adenoma 30.5 MUC1 KRAS APC
46 transverse colon cancer 30.5 KRT7 KRAS
47 adenomyoma 30.5 MUC4 MUC1 KRT7
48 papillary carcinoma 30.5 MUC1 KRT7 KRT19
49 wilms tumor 1 30.4 TP53 KRT7 KRAS AFP
50 gastrointestinal carcinoma 30.4 TP53 MUC1 KRT19

Graphical network of the top 20 diseases related to Intrahepatic Cholangiocarcinoma:



Diseases related to Intrahepatic Cholangiocarcinoma

Symptoms & Phenotypes for Intrahepatic Cholangiocarcinoma

UMLS symptoms related to Intrahepatic Cholangiocarcinoma:


abdominal pain, malaise

GenomeRNAi Phenotypes related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.5 AFP
2 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.5 AFP
3 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.5 APC
4 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.5 KRT7
5 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.5 APC
6 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.5 AFP APC KRT7
7 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.5 APC
8 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.5 AFP APC
9 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.5 APC
10 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.5 AFP
11 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.5 APC KRT7

Drugs & Therapeutics for Intrahepatic Cholangiocarcinoma

Drugs for Intrahepatic Cholangiocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 309)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
2
Desflurane Approved Phase 4 57041-67-5 42113
3
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
4
Etomidate Approved Phase 4 33125-97-2 667484 36339
5 Anti-Inflammatory Agents, Non-Steroidal Phase 4
6 Cyclooxygenase 2 Inhibitors Phase 4
7 Cyclooxygenase Inhibitors Phase 4
8 Anesthetics, Inhalation Phase 4
9 Platelet Aggregation Inhibitors Phase 4
10 Analgesics Phase 4
11
Bismuth Phase 4 7440-69-9 16682734 105143
12 Ulipristal acetate Phase 4 126784-99-4
13 Omega 3 Fatty Acid Phase 4
14 Narcotics Phase 4
15 Central Nervous System Depressants Phase 4
16 Anesthetics, Intravenous Phase 4
17 Hypnotics and Sedatives Phase 4
18 Anesthetics, General Phase 4
19 Analgesics, Opioid Phase 4
20 Adjuvants, Anesthesia Phase 4
21 Tranquilizing Agents Phase 4
22 GABA Agents Phase 4
23 GABA Modulators Phase 4
24 Anti-Anxiety Agents Phase 4
25
Arginine Investigational, Nutraceutical Phase 4 74-79-3 6322
26
Irinotecan Approved, Investigational Phase 2, Phase 3 100286-90-6, 97682-44-5 60838
27
nivolumab Approved Phase 3 946414-94-4
28
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
29
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
30
Ipilimumab Approved Phase 3 477202-00-9
31
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 6857599 43805
32
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
33
Simvastatin Approved Phase 3 79902-63-9 54454
34
Fluorouracil Approved Phase 3 51-21-8 3385
35
leucovorin Approved Phase 3 58-05-9 6006 143
36
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
37
Citalopram Approved Phase 3 59729-33-8 2771
38
Calcium Approved, Nutraceutical Phase 2, Phase 3 7440-70-2 271
39
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
40 Anti-Ulcer Agents Phase 3
41 Antacids Phase 3
42 Antiparasitic Agents Phase 3
43 Anthelmintics Phase 3
44 Calcium, Dietary Phase 2, Phase 3
45 Hematinics Phase 3
46 Trace Elements Phase 3
47 Anti-Bacterial Agents Phase 3
48 Vitamins Phase 3
49 Micronutrients Phase 3
50 Nutrients Phase 3

Interventional clinical trials:

(show top 50) (show all 535)
# Name Status NCT ID Phase Drugs
1 Effect of Preoperative Biliary Drainage on Postoperative Complications in Resectable Patients With Hilar Cholangiocarcinoma(Klatskin Tumor) Unknown status NCT00797121 Phase 4
2 Quality of Life in Patients With Unresectable Hilar Cholangiocarcinoma on Palliative Metallic Stent Versus Plastic Stent: A Randomized Control Trial Unknown status NCT00746538 Phase 4
3 Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Hepatectomy Unknown status NCT01256047 Phase 4
4 Prospective, Randomized, Open-label, Controlled Trial of Cyclooxygenase-2 Inhibitor (Celecoxib; Celebrex®) for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer. Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
5 Effects of Different Inhalational Anesthetic Agents on the Incidence of Clinical and Subclinical Acute Kidney Injury After Liver Resection Surgery: a Pilot Study Unknown status NCT02174575 Phase 4 Sevoflurane;Desflurane
6 Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Unresectable Complex Hilar Cholangiocarcinoma; a Randomized Controlled Trial Completed NCT00721175 Phase 4
7 Covered Versus Uncovered Metal Stents for Management of Distal Malignant Biliary Obstruction? Results of a Randomized Prospective Study. Completed NCT00280709 Phase 4
8 Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
9 Pilot Study: Randomized Controlled Trial on the Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4 oral nutritional supplement rich in eicosapentanoic acid
10 Re-intervention for Occluded Biliary Metal Stent in Malignant Distal Bile Duct Obstruction: a Prospective Randomized Multi-center Trial Comparing Covered and Uncovered Metal Stent Completed NCT01315522 Phase 4
11 Etomidate With Meperidine vs Midazolam With Meperidine for Sedation During Endodscopic Retrograde Cholangiopancreatogram (ERCP) Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
12 Endoscopic Radiofrequency Ablation for Malignant Biliary Obstruction Completed NCT01758341 Phase 4
13 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy for Periampullary Tumors: a Prospective, Randomized, Controlled Clinical Trial Recruiting NCT01642875 Phase 4
14 Oxaliplatin Plus Gemcitabine Versus Capecitabine Alone as Adjuvant Treatment in the Prevention of Recurrence of Intrahepatic Cholangiocarcinoma Unknown status NCT02548195 Phase 3 oxaliplatin and gemcitabine;capecitabine
15 A Randomized Controlled Trial Comparing Endoscopic Biliary Radiofrequency Ablation With Photodynamic Therapy for Inoperable Cholangiocarcinoma Unknown status NCT01739465 Phase 2, Phase 3
16 Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma Unknown status NCT02798510 Phase 3 capecitabine;gemcitabine
17 Unilateral Versus Bilateral Stents for Bismuth Type II and III Malignant Hilar Strictures: A Prospective, Multi-center Randomized Controlled Trial Unknown status NCT00653978 Phase 3
18 Open-label Observational Study of Plastic Cylindrical Fiber Optic Diffuser (Pioneer Optics) in Photodynamic Therapy for the Management of Cholangiocarcinoma. Unknown status NCT01755013 Phase 2, Phase 3
19 A Prospective, Randomized Trial of Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
20 Phase III Multicenter Randomized Study Comparing the Effect of Adjuvant Chemotherapy for Six Months With Gemcitabine-Oxaliplatin 85 mg/m2 (GEMOX 85) to Observation in Patients Who Underwent Surgery for Cancer of the Bile Ducts Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
21 A Randomised Clinical Trial Evaluating Adjuvant Chemotherapy With Capecitabine Compared to Expectant Treatment Alone (Observation) Following Surgery for Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
22 Photodynamic Therapy With S-1 in the Patients With Unresectable Type III or IV Cholangiocarcinoma: A Prospective Randomized Trial With Open Label Control Completed NCT00869635 Phase 3 S-1 Chemotherapy
23 Gemcitabine, Alone or in Combination With Cisplatin, in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumors: A Multicentre, Randomized Phase III Study Completed NCT00262769 Phase 3 cisplatin;gemcitabine hydrochloride
24 Porfimer Sodium Photodynamic Therapy Plus Stenting Versus Stenting Alone in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumours: a Multicentre, Randomised, Phase Lll Study Completed NCT00513539 Phase 3 porfimer sodium
25 Randomized Phase II-III Study of Chemoradiation With Fluorouracil and Cisplatin Versus Chemotherapy (Gemcitabine/Oxaliplatin) in Non Resectable But Non Metastatic Cancer of the Biliary Tract Completed NCT00304135 Phase 2, Phase 3 cisplatin;gemcitabine hydrochloride;oxaliplatin
26 Sequential Preoperative Ipsilateral Hepatic Vein Embolization After Portal Vein Embolization to Induce Further Liver Regeneration in Patients With Hepatobiliary Malignancy Completed NCT00698880 Phase 2, Phase 3
27 The Efficacy of Levamisole Hcl in Advanced Intrahepatic Cholangiocarcinoma . A Multicenter, Open, Randomized, Prospective Study Recruiting NCT03940378 Phase 3 Levamisole Hydrochloride;Anlotinib Hydrochloride Capsules
28 Hepatic Arterial Infusion Chemotherapy of Irinotecan, Oxaliplatin, 5-Fluorouracil and Leucovorin Versus Systemic Chemotherapy of Gemcitabine and Oxaliplatin for Unresectable Intrahepatic Cholangiocarcinoma Recruiting NCT03771846 Phase 3 irinotecan, oxaliplatin , fluorouracil, and leucovorin;gemcitabine and oxaliplatin
29 Bortezomib in Treating Patients With Intrahepatic Cholangiocellular Carcinoma Featuring PTEN Deficiency Recruiting NCT03345303 Phase 3 Bortezomib
30 Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC (ICC/ECC) - A Phase III Study of the German Registry of Incidental Gallbladder Carcinoma Platform (GR) - The AIO/ CALGP/ ACO- GAIN-Trial - Recruiting NCT03673072 Phase 3 Gemcitabine;Cisplatin;Adjuvant chemotherapy
31 Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine Versus Cisplatin/Gemcitabine in Patients With IntraHepatic Cholangiocarcinoma Recruiting NCT03086993 Phase 2, Phase 3 Cisplatin and Gemcitabine
32 A Randomized, Open, Multi-center Phase IIb/III Clinical Study to Assess the Efficacy and Safety of Surufatinib Compared to Capecitabine in Advanced or Metastatic Biliary Tract Carcinoma (BTC) Patients Recruiting NCT03873532 Phase 2, Phase 3 Surufatinib;Capecitabine
33 A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: The PROOF Trial Recruiting NCT03773302 Phase 3 BGJ398;Gemcitabine;Cisplatin
34 A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302) Recruiting NCT03656536 Phase 3 Pemigatinib;Gemcitabine;Cisplatin
35 Percutaneous Bilateral Versus Unilateral Metal Stent Placement for Hilar Cholangiocarcinoma : A Prospective Open-label Randomized Controlled Trial Recruiting NCT02108145 Phase 2, Phase 3
36 Phase III Randomized Trial of High Dose Chemoradiation and Systemic Chemotherapy vs Systemic Chemotherapy Alone in Patients With Unresectable Nonmetastatic Cholangiocarcinoma Recruiting NCT02773485 Phase 3 Systemic chemotherapy
37 Adjuvant Chemotherapy With Gemcitabine and Capecitabine Compared to Capecitabine for Biliary Tract Cancer After Curative Resection Recruiting NCT03779035 Phase 3 Gemcitabine;Capecitabine
38 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial) Recruiting NCT02170090 Phase 3 Gemcitabine;Cisplatin;Capecitabine
39 A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without M7824(Bintrafusp Alfa) as First-line Treatment of Biliary Tract Cancer Recruiting NCT04066491 Phase 2, Phase 3 M7824;Placebo;Gemcitabine;Cisplatin
40 Phase III Randomized, Placebo-controlled Clinical Trial of Hepcortespenlisimut-L (Hepko-V5) Versus Placebo in Patients With Advanced Hepatocellular Carcinoma (HCC) Recruiting NCT02232490 Phase 3
41 A Phase III Open-Label, Multi-Centre, Randomized Study Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer Recruiting NCT04163900 Phase 3 NUC-1031;Gemcitabine;Cisplatin
42 A Randomized Non-inferiority Trial Evaluating the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors Recruiting NCT04157985 Phase 3 Continue PD-1/PD-L1 Inhibitors treatment
43 A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants With Advanced and/or Unresectable Biliary Tract Carcinoma Recruiting NCT04003636 Phase 3 Pembrolizumab;Gemcitabine;Cisplatin;Placebo
44 A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers Recruiting NCT03768414 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
45 Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours Recruiting NCT02591030 Phase 2, Phase 3 GEMCIS;mFolfirinox
46 Impact of Early Palliative Care on Overall Survival of Patients With Metastatic Upper Gastrointestinal Cancers, Treated With First-line Chemotherapy: a Randomized Phase III Trial Recruiting NCT02853474 Phase 3
47 Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma Active, not recruiting NCT02807181 Phase 2, Phase 3 Cisplatin-gemcitabine
48 Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma Active, not recruiting NCT02482454 Phase 2, Phase 3
49 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation Active, not recruiting NCT02989857 Phase 3 AG-120;AG-120 matched placebo
50 A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of GEMOX(Gemcitabine/Oxaliplatin) vs XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma Active, not recruiting NCT01470443 Phase 3 Oxaliplatin;Oxaliplatin

Search NIH Clinical Center for Intrahepatic Cholangiocarcinoma

Cochrane evidence based reviews: cholangiocarcinoma

Genetic Tests for Intrahepatic Cholangiocarcinoma

Anatomical Context for Intrahepatic Cholangiocarcinoma

MalaCards organs/tissues related to Intrahepatic Cholangiocarcinoma:

40
Liver, Lymph Node, T Cells, Pancreas, Colon, Breast, Lung

Publications for Intrahepatic Cholangiocarcinoma

Articles related to Intrahepatic Cholangiocarcinoma:

(show top 50) (show all 11521)
# Title Authors PMID Year
1
MicroRNA profiling of human intrahepatic cholangiocarcinoma cell lines reveals biliary epithelial cell-specific microRNAs. 46 61
19755794 2009
2
Gramicidin inhibits cholangiocarcinoma cell growth by suppressing EGR4. 61
31852273 2020
3
Foreign body granuloma reaction following SIRT mimicking peritoneal metastases: a word of caution. 61
30092710 2020
4
Prognostic value of neutrophil-to-lymphocyte ratio and its correlation with fluorine-18-fluorodeoxyglucose metabolic parameters in intrahepatic cholangiocarcinoma submitted to 90Y-radioembolization. 61
31800510 2020
5
Behavior-related risk factors for opisthorchiasis-associated cholangiocarcinoma among rural people living along the mekong river in five greater mekong subregion countries. 61
31654901 2020
6
Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with and without risks: the evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version 2017. 61
31297632 2020
7
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis. 61
31536748 2020
8
Glutamine deprivation counteracts hypoxia-induced chemoresistance. 61
31765939 2020
9
Liver transplantation for hilar cholangiocarcinoma: A systematic review. 61
31711828 2020
10
Effectiveness of surgery for recurrent cholangiocarcinoma: A single center experience and brief literature review. 61
30797594 2020
11
Increased odds of cholangiocarcinoma in Hispanics: results of a nationwide analysis. 61
31651656 2020
12
PTPN3 suppresses the proliferation and correlates with favorable prognosis of perihilar cholangiocarcinoma by inhibiting AKT phosphorylation. 61
31706106 2020
13
The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinoma. 61
31605774 2020
14
Cholangiolar pattern and albumin in situ hybridisation enable a diagnosis of intrahepatic cholangiocarcinoma. 61
31422372 2020
15
Integrating next-generation sequencing to endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens improves the detection and management of patients with malignant bile duct strictures. 61
30971436 2020
16
Redefining Conditional Overall and Disease-Free Survival After Curative Resection for Intrahepatic Cholangiocarcinoma: a Multi-institutional, International Study of 1221 patients. 61
31823320 2019
17
Reply to the Letter: "Laparoscopic Hepatectomy Has Superiority in R0 Resection over Open Hepatectomy for Intrahepatic Cholangiocarcinoma? The Evidence Is Unreliable". 61
31823325 2019
18
Does high-grade dysplasia/carcinoma in situ of the biliary duct margin affect the prognosis of extrahepatic cholangiocarcinoma? A meta-analysis. 61
31818290 2019
19
Nodal CTV selection according to primary tumour location and pT stage for biliary tract cancer. 61
31402569 2019
20
Liver Transplantation for Non-hepatocellular Carcinoma Malignancy: A Single-Center Experience. 61
31669072 2019
21
Associations between Prediagnostic Concentrations of Circulating Sex Steroid Hormones and Liver Cancer Among Post-Menopausal Women. 61
31808181 2019
22
Somatic mutation signatures in primary liver tumors of workers exposed to ionizing radiation. 61
31796844 2019
23
A metastatic skull tumor from intrahepatic cholangiocarcinoma: A case report and literature review. 61
31804374 2019
24
Metabolic rearrangements in primary liver cancers: cause and consequences. 61
31666728 2019
25
A review of changes to and clinical implications of the eighth TNM classification of hepatobiliary and pancreatic cancers. 61
31822900 2019
26
HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis. 61
31805897 2019
27
Upregulation of miR‑132‑3p in cholangiocarcinoma tissues: A study based on RT‑qPCR, The Cancer Genome Atlas miRNA sequencing, Gene Expression Omnibus microarray data and bioinformatics analyses. 61
31638221 2019
28
ASO Author Reflections: Association of Perioperative Red Blood Cell Transfusion with Increased Disease Recurrence and Worse Survival After Resection of Distal Cholangiocarcinoma. 61
31286311 2019
29
Modifications of the AJCC 8th edition staging system for intrahepatic cholangiocarcinoma and proposal for a new staging system by incorporating serum tumor markers. 61
31307889 2019
30
Chemoembolization with Degradable Starch Microspheres for Treatment of Patients with Primary or Recurrent Unresectable, Locally Advanced Intrahepatic Cholangiocarcinoma: A Pilot Study. 61
31578633 2019
31
Effect of Educational Intervention Based on the Health Belief Model and Self-Efficacy in Promoting Preventive Behaviors in a Cholangiocarcinoma Screening Group. 61
30244403 2019
32
Up-regulation of ZFAS1 indicates dismal prognosis for cholangiocarcinoma and promotes proliferation and metastasis by modulating USF1 via miR-296-5p. 61
31565837 2019
33
Genetically engineered animal models of biliary tract cancers. 61
31850929 2019
34
Klatskin-mimicking neuroendocrine tumor. 61
31696723 2019
35
Prognostic value of preoperative inflammatory markers in resectable biliary tract cancer - Validation and comparison of the Glasgow Prognostic Score and Modified Glasgow Prognostic Score in a Western cohort. 61
31848078 2019
36
Endogenous CXCL9 affects prognosis by regulating tumor-infiltrating NK cells in intrahepatic cholangiocarcinoma. 61
31799781 2019
37
Combining imaging and tumour biopsy improves the diagnosis of combined hepatocellular-cholangiocarcinoma. 61
31544304 2019
38
Novel IDH1-Targeted Glioma Therapies. 61
31768950 2019
39
MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways. 61
31837357 2019
40
Protective effect of phosphatidylcholine on lysophosphatidylcholine-induced cellular senescence in cholangiocyte. 61
31578786 2019
41
Pancreaticoduodenectomy following surgery for esophageal cancer with gastric tube reconstruction: a case report and literature review. 61
31811418 2019
42
MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers. 61
31568700 2019
43
Long noncoding RNA SOX2-OT facilitates prostate cancer cell proliferation and migration via miR-369-3p/CFL2 axis. 61
31623830 2019
44
Photoimmunotherapy targeting biliary-pancreatic cancer with humanized anti-TROP2 antibody. 61
31674732 2019
45
SPARC expression in desmoplastic and non desmoplastic pancreatic carcinoma and cholangiocarcinoma. 61
31727501 2019
46
Glucose Depletion Enhances the Stem Cell Phenotype and Gemcitabine Resistance of Cholangiocarcinoma Organoids through AKT Phosphorylation and Reactive Oxygen Species. 61
31835877 2019
47
A runaway PRH/HHEX-Notch3 positive feedback loop drives cholangiocarcinoma and determines response to CDK4/6 inhibition. 61
31843982 2019
48
Radiomics model of magnetic resonance imaging for predicting pathological grading and lymph node metastases of extrahepatic cholangiocarcinoma. 61
31809800 2019
49
Sprouty4 correlates with favorable prognosis in perihilar cholangiocarcinoma by blocking the FGFR-ERK signaling pathway and arresting the cell cycle. 61
31761616 2019
50
Letter to the Editor: Short- and Long-Term Outcomes of Liver Resection for Intrahepatic Cholangiocarcinoma Associated with the Metabolic Syndrome. 61
31822945 2019

Variations for Intrahepatic Cholangiocarcinoma

ClinVar genetic disease variations for Intrahepatic Cholangiocarcinoma:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 APC NM_000038.6(APC):c.8332G>T (p.Ala2778Ser)SNV Conflicting interpretations of pathogenicity 133537 rs587778046 5:112179623-112179623 5:112843926-112843926
2 APC NM_000038.6(APC):c.4440G>C (p.Gln1480His)SNV Uncertain significance 482375 rs876659881 5:112175731-112175731 5:112840034-112840034
3 APC NM_000038.6(APC):c.8461G>A (p.Asp2821Asn)SNV Uncertain significance 559959 rs1554089164 5:112179752-112179752 5:112844055-112844055

Expression for Intrahepatic Cholangiocarcinoma

Search GEO for disease gene expression data for Intrahepatic Cholangiocarcinoma.

Pathways for Intrahepatic Cholangiocarcinoma

Pathways related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.64 TP53 KRAS IDH1
2
Show member pathways
10.07 IDH2 IDH1

GO Terms for Intrahepatic Cholangiocarcinoma

Biological processes related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.32 TP53 MUC1
2 NADP metabolic process GO:0006739 9.26 IDH2 IDH1
3 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.16 TP53 MUC1
4 isocitrate metabolic process GO:0006102 8.96 IDH2 IDH1
5 glyoxylate cycle GO:0006097 8.62 IDH2 IDH1

Molecular functions related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.96 IDH2 IDH1
2 isocitrate dehydrogenase activity GO:0004448 8.62 IDH2 IDH1

Sources for Intrahepatic Cholangiocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....